LOGIQ™ E10 Ultrasound Series
Next-generation, leadership ultrasound that adapts to your needs, today and into the future. Choose from a wide array of advanced imaging tools and robust productivity enhancers based on artificial intelligence—all on a scalable platform that lets you configure your system specifically to the needs of your practice.
Take advantage of our most technologically-advanced ultrasound ever to bring fast, precise, consistent imaging to your patients—your way— with the LOGIQ E10 Series.
SIGNA™ PET/MR with QuantWorks – 60cmIntroducing SIGNA™ PET/MR with QuantWorks. Built with pioneering TOF and integrated with a 3.0T MR.
READY ViewQuantified MR image analysis to enable accurate, confident diagnoses.
9. Breast Cancer Res. 2017 Sep 11;19(1):106. doi: 10.1186/s13058-017-0899-1.Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging. Iotti V1, Ravaioli S2, Vacondio R2, Coriani C2, Caffarri S3, Sghedoni R4, Nitrosi A4, Ragazzi M5, Gasparini E6, Masini C7, Bisagni G7, Falco G8, Ferrari G8, Braglia L9, Del Prato A2, Malavolti I3, Ginocchi V3, Pattacini P2. Breast Cancer Res. 2017 Sep 11;19(1):106. doi: 10.1186/s13058-017-0899-1.
10. Mammography,Imaging Neoadjuvant Therapy.Response in Breast Cancer. Amy M. Fowler, MD, PhDDavid A. Mankoff, MD, PhD,Bonnie N. Joe, MD, PhD. radiology.rsna.org n Radiology: Volume 285: Number 2—November 2017
11. 18F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer. Stefanie Avril, Raymond F. Muzic Jr., Donna Plecha, Bryan J. Traughber, Shaveta Vinayak, and Norbert Avril. Nucl Med. 2016 February ; 57(Suppl 1): 34S–39S. doi:10.2967/jnumed.115.157875.